Fem Pro Drops

Dosage for Beta-endorphin Human is highly individualized and depends on the route of administration and the condition being treated. Because it is a potent peptide, doses are often measured in micrograms (mcg) or milligrams (mg).

• For Intractable Pain (Intrathecal): A typical starting dose may range from 1 mg to 5 mg, administered as a single bolus by a specialist. Maintenance doses are determined based on patient response and tolerance.
• For Systemic Research (Intravenous): Doses may range from 0.1 mg/kg to 0.5 mg/kg of body weight, depending on the clinical protocol.
• For Hormonal Modulation: Dosing is experimental and varies widely based on the specific endocrine target.

Beta-endorphin Human is not currently FDA-approved for use in pediatric patients. The safety and efficacy of synthetic beta-endorphin in children have not been established. Use in this population is generally restricted to highly controlled clinical trials. Healthcare providers will weigh the risks of opioid-related side effects, which can be more severe in children, against potential benefits.

Renal Impairment

Because Beta-endorphin is primarily cleared by peptidases in the blood and tissues rather than through the kidneys, significant dose adjustments for renal impairment are not typically required. However, patients with end-stage renal disease (ESRD) should be monitored closely for secondary metabolic changes.

Hepatic Impairment

Similar to renal impairment, hepatic (liver) function does not significantly alter the primary metabolic pathway of Beta-endorphin. However, since the liver produces many of the enzymes involved in peptide degradation, patients with severe hepatic failure (Child-Pugh Class C) should be approached with caution.

Elderly Patients

Geriatric patients often have a higher sensitivity to opioid agonists. Healthcare providers typically start at the lower end of the dosing range (e.g., 25-50% of the standard adult dose) to minimize the risk of respiratory depression, sedation, and falls.

Beta-endorphin Human is almost exclusively administered by a healthcare professional.

• Clinical Setting: It is usually given in a hospital, surgery center, or pain clinic.
• Administration: If given intrathecally, it requires a spinal tap procedure. If given intravenously, it should be infused slowly to monitor for immediate reactions.
• Storage: The medication must be stored in a refrigerator (2°C to 8°C) and protected from light. Once reconstituted, it must be used within a specific timeframe (usually 24 hours) to ensure potency.

Since Beta-endorphin Human is typically administered on a fixed schedule in a clinical setting or as a one-time procedure, missed doses are rare. If a scheduled infusion is missed, contact your healthcare provider immediately to reschedule. Do not attempt to 'double up' on doses if you are using an implantable pump system.

An overdose of Beta-endorphin Human is a medical emergency and presents similarly to a morphine overdose.

• Signs: Pinpoint pupils (miosis), extreme drowsiness, slowed or stopped breathing (respiratory depression), and cold, clammy skin.
• Emergency Measures: If an overdose is suspected, call 911 or emergency services immediately. The opioid antagonist Naloxone (Narcan) is the standard treatment to reverse the effects of Beta-endorphin overdose. Support of the airway and mechanical ventilation may be required.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or administration schedule without direct medical guidance.

As a potent opioid and hormonal modulator, Beta-endorphin Human can cause several common side effects. These are typically dose-dependent and may include:

• Nausea and Vomiting: This is the most frequent side effect, occurring as the body adjusts to increased opioid receptor activity. It often subsides after the first few doses.
• Pruritus (Itching): A common reaction to opioid agonists, often felt on the face, neck, or chest. It is caused by histamine release.
• Somnolence (Drowsiness): Patients may feel an intense urge to sleep or feel 'foggy.'
• Dizziness: Especially when moving from a sitting to a standing position (orthostatic hypotension).
• Constipation: Opioids slow down the movement of the digestive tract. Unlike other side effects, tolerance to constipation rarely develops.

• Urinary Retention: Difficulty starting urination or fully emptying the bladder, more common with spinal administration.
• Dry Mouth (Xerostomia): A decrease in saliva production.
• Hyperhidrosis (Excessive Sweating): Sudden bouts of sweating, often related to the drug's effect on the hypothalamus.
• Mood Changes: Including euphoria (intense happiness) or dysphoria (unease/anxiety).

• Hallucinations: Seeing or hearing things that are not there.
• Muscle Rigidity: Particularly in the chest wall, which can interfere with breathing.
• Bradycardia: An abnormally slow heart rate.
• Anaphylaxis: A severe, life-threatening allergic reaction (rare but possible given its allergenic extract classification).

> Warning: Stop the administration (if applicable) and call your doctor immediately or seek emergency care if you experience any of the following:

1. 1Respiratory Depression: Breathing that is too shallow or too slow (less than 8-10 breaths per minute). This is the most dangerous side effect of Beta-endorphin Human.
2. 2Severe Hypotension: A sudden drop in blood pressure leading to fainting or loss of consciousness.
3. 3Serotonin Syndrome: If used with other medications, symptoms include agitation, high fever, tremors, and rapid heart rate.
4. 4Seizures: Uncontrolled electrical activity in the brain, which can occur at very high doses.
5. 5Chest Pain: Could indicate cardiovascular stress or the rare side effect of coronary vasospasm.

Prolonged use of Beta-endorphin Human can lead to several chronic issues:

• Opioid Use Disorder (Addiction): Even though it is a 'natural' peptide, synthetic administration can lead to physical dependence and addiction.
• Tolerance: Over time, higher doses may be required to achieve the same level of pain relief.
• Hormonal Suppression: Long-term use can suppress the body's natural production of endorphins, testosterone, and estrogen, leading to sexual dysfunction, infertility, and osteoporosis (brittle bones).
• Immune System Modulation: Chronic opioid use may weaken the immune system's ability to fight infections.

While Beta-endorphin Human is often used in research, any synthetic opioid agonist of this potency carries implied Black Box Warnings similar to those for morphine and fentanyl:

• Risk of Medication Errors: Ensure the correct concentration and route (intrathecal vs. IV) are used, as errors can be fatal.
• Addiction, Abuse, and Misuse: This drug exposes users to the risks of opioid addiction, which can lead to overdose and death.
• Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can result in life-threatening withdrawal in the newborn.

Report any unusual symptoms or side effects to your healthcare provider immediately.

Beta-endorphin Human is a high-alert medication. It must only be administered by clinicians experienced in the management of potent opioids and the use of intrathecal or intravenous infusions. Patients must be monitored in a setting where resuscitative equipment (including oxygen and naloxone) is immediately available.

No specific FDA black box warning exists exclusively for 'Beta-endorphin Human' as a standalone commercial product in the same way as OxyContin; however, as an opioid agonist, it falls under the class-wide FDA warnings for all potent opioids. These include the high potential for Addiction, Abuse, and Misuse, and the critical risk of Fatal Respiratory Depression. Furthermore, the use of opioids with benzodiazepines or other central nervous system (CNS) depressants may result in profound sedation, respiratory depression, coma, and death.

• Allergic Reactions / Anaphylaxis Risk: Because Beta-endorphin Human is classified as a 'Non-Standardized Plant/Food Allergenic Extract' in some databases, there is a risk of cross-reactivity in patients with severe environmental or food allergies. Signs of anaphylaxis include swelling of the face, hives, and difficulty swallowing.
• Hepatotoxicity and Nephrotoxicity: While the drug is not primarily cleared by these organs, pre-existing failure can slow the body's overall ability to maintain homeostasis during treatment.
• Head Injury and Increased Intracranial Pressure: Beta-endorphin can increase the pressure of the fluid in the brain. It should be used with extreme caution in patients with head injuries or brain tumors.
• Gastrointestinal Conditions: It may obscure the diagnosis of 'acute abdomen' (severe abdominal pain) or worsen conditions like paralytic ileus (paralyzed bowel).

Patients receiving Beta-endorphin Human require frequent clinical assessment:

1. 1Respiratory Rate and Oxygen Saturation: Continuous monitoring during and immediately after administration.
2. 2Blood Pressure and Heart Rate: To detect hypotension or bradycardia.
3. 3Pain Scales: To assess the efficacy of the treatment.
4. 4Endocrine Function: For long-term users, regular blood tests for testosterone, estrogen, and cortisol levels are recommended.

Do NOT drive, operate heavy machinery, or engage in potentially hazardous activities until you know how Beta-endorphin Human affects you. This medication causes significant sedation and can impair your coordination and reaction time.

Alcohol must be strictly avoided. Consuming alcohol while taking Beta-endorphin Human significantly increases the risk of fatal respiratory depression and profound sedation. This includes 'hidden' alcohol in over-the-counter cough syrups.

Do not stop taking Beta-endorphin Human suddenly if you have been using it for an extended period. Sudden discontinuation can trigger a withdrawal syndrome, characterized by anxiety, tremors, sweating, muscle aches, and diarrhea. Your doctor will provide a tapering schedule to slowly reduce the dose.

> Important: Discuss all your medical conditions, especially respiratory issues like asthma or COPD, with your healthcare provider before starting Beta-endorphin Human.

• Mixed Agonist/Antagonist Opioids (e.g., Buprenorphine, Pentazocine): These can reduce the analgesic effect of Beta-endorphin and may precipitate withdrawal symptoms in dependent patients.
• MAO Inhibitors (e.g., Phenelzine, Selegiline): Using these within 14 days of Beta-endorphin can lead to unpredictable, severe reactions including excitation, sweating, and extreme blood pressure changes.

• Benzodiazepines (e.g., Lorazepam, Diazepam): Combining these with Beta-endorphin significantly increases the risk of fatal respiratory depression. This combination should only be used if no alternative exists, and at the lowest possible doses.
• Other CNS Depressants: This includes muscle relaxants (e.g., Cyclobenzaprine), sleep medications (e.g., Zolpidem), and other opioids. These drugs add to the sedative effects of Beta-endorphin.
• Anticholinergic Drugs: When used with Beta-endorphin (which has nicotinic agonist properties), there is an increased risk of urinary retention and severe constipation.

• Estrogen-Containing Medications: Since Beta-endorphin acts as an Estrogen Receptor Agonist, it may interfere with or enhance the effects of birth control pills or hormone replacement therapy (HRT).
• Diuretics: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone (ADH).

• High-Fat Meals: While Beta-endorphin is usually injected, if any oral analogs are used, high-fat meals can significantly alter the rate of absorption.
• Grapefruit Juice: Although not a major CYP3A4 substrate, grapefruit juice can affect the metabolism of many co-administered medications, potentially increasing the risk of side effects.

• St. John's Wort: May decrease the plasma concentration of opioids by inducing metabolic enzymes.
• Valerian and Kava: These herbal sedatives can increase the drowsiness caused by Beta-endorphin.
• Magnesium: Some studies suggest magnesium may enhance the pain-relieving effects of opioids but also increase sedation.

• Amylase/Lipase: Beta-endorphin can cause spasms of the Sphincter of Oddi, which may lead to temporary elevations in these pancreatic enzymes, potentially mimicking a diagnosis of pancreatitis.
• Urine Drug Screens: Synthetic beta-endorphin may or may not show up on standard 'opiate' screens depending on the specific antibodies used in the test.

For each major interaction, the primary mechanism is usually pharmacodynamic synergism (where two drugs work together to increase an effect like sedation) or receptor competition. Management strategies always involve dose reduction and vigilant monitoring by a healthcare professional.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those for allergies or sleep.

Beta-endorphin Human must NEVER be used in the following circumstances:

1. 1Significant Respiratory Depression: Patients with pre-existing severe asthma, COPD, or hypoventilation should not receive this drug as it can stop their breathing entirely.
2. 2Acute or Severe Bronchial Asthma: Especially in unmonitored settings or in the absence of resuscitative equipment.
3. 3Gastrointestinal Obstruction: Including known or suspected paralytic ileus, as the drug will stop all bowel movement.
4. 4Hypersensitivity: Known allergy to beta-endorphin, morphine, or any of the excipients in the formulation. Given its classification as a 'Standardized Chemical Allergen,' patients with a history of multiple chemical sensitivities should be evaluated carefully.

Conditions requiring a careful risk-benefit analysis include:

• History of Substance Abuse: Due to the high risk of addiction and relapse.
• Biliary Tract Disease: Including acute pancreatitis, as the drug can cause biliary spasms.
• Seizure Disorders: Opioids can lower the seizure threshold in susceptible individuals.
• Hypothyroidism: These patients may be more sensitive to the sedative and respiratory-depressant effects.
• Prostatic Hypertrophy: Men with enlarged prostates are at high risk for acute urinary retention.

Patients who have had severe allergic reactions to other opioid peptides (like Enkephalins) or certain 'Plant Allergenic Extracts' should be cautious. Because Beta-endorphin is a human-sequence peptide, true allergic reactions are rare but can occur if the product is contaminated or if the patient has developed antibodies to synthetic peptide sequences.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of sleep apnea or depression, before prescribing Beta-endorphin Human.

Beta-endorphin Human is generally classified as Pregnancy Category C (or the equivalent under newer FDA labeling). There are no adequate and well-controlled studies in pregnant women.

• Teratogenicity: Animal studies have shown that high doses of opioids can affect fetal development and brain maturation.
• Labor and Delivery: Use during labor can cause respiratory depression in the newborn.
• Chronic Use: If used chronically during pregnancy, the baby may be born with Neonatal Opioid Withdrawal Syndrome (NOWS), which requires specialized neonatal intensive care.

It is not known whether synthetic Beta-endorphin is excreted in human milk. However, most opioid peptides and estrogenic compounds do pass into breast milk.

• Risk to Infant: Nursing infants may experience excessive somnolence, difficulty breastfeeding, and respiratory depression.
• Recommendation: Breastfeeding is generally not recommended while receiving acute or chronic Beta-endorphin therapy. If used, the infant must be monitored closely for 'limpness' or breathing problems.

As previously noted, Beta-endorphin Human is not approved for use in children. The pediatric population is more susceptible to the respiratory-depressant effects of opioids. In rare cases where it is used (e.g., terminal illness), dosing must be calculated strictly by body weight and administered by a pediatric pain specialist.

Elderly patients (65 years and older) are at increased risk for adverse reactions.

• Pharmacokinetics: Reduced renal and hepatic clearance can lead to drug accumulation.
• Safety Concerns: Increased risk of confusion, delirium, and falls.
• Polypharmacy: Older adults are often on multiple medications (e.g., for blood pressure or sleep), increasing the risk of dangerous drug interactions.

While the primary metabolism is peptidase-driven, renal failure can lead to the accumulation of metabolites that may have neurotoxic effects. A 25-50% dose reduction may be considered for patients with a GFR (Glomerular Filtration Rate) below 30 mL/min.

In patients with severe hepatic impairment, the production of plasma peptidases may be decreased, potentially prolonging the half-life of Beta-endorphin. Monitoring for increased sedation is essential in this population.

> Important: Special populations require individualized medical assessment and often more frequent monitoring of vital signs and blood work.

Beta-endorphin Human is a 31-amino acid endogenous opioid peptide derived from the precursor protein Pro-opiomelanocortin (POMC). Its primary mechanism involves binding to mu-opioid receptors (MOR) in the brain and spinal cord. Upon binding, it activates G-protein coupled receptors, which inhibits adenylate cyclase, closes voltage-gated calcium channels, and opens potassium channels. This results in hyperpolarization of the neuron, making it less likely to fire and transmit pain signals.

Additionally, its classification as a Cholinergic Nicotinic Agonist suggests it interacts with alpha-7 nicotinic acetylcholine receptors, which are involved in anti-inflammatory pathways and neuroprotection. As an Estrogen Receptor Agonist, it can bind to ER-alpha and ER-beta, influencing gene expression related to reproductive health and bone density.

• Onset of Action: Intrathecal (5-10 minutes); Intravenous (1-2 minutes).
• Peak Effect: 30-60 minutes.
• Duration: 2-6 hours for systemic administration; up to 24 hours for intrathecal administration.
• Tolerance: Repeated administration leads to down-regulation of opioid receptors, requiring higher doses for the same effect.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV/Intrathecal); <1% (Oral) |

| Protein Binding | 40-60% (primarily Albumin) |

| Half-life | 15-30 minutes (Plasma) |

| Tmax | Immediate (IV) |

| Metabolism | Rapidly cleaved by Peptidases (e.g., Insulin-degrading enzyme) |

| Excretion | Renal <5% (as intact peptide); primarily as amino acid fragments |

• Molecular Formula: C158H251N39O46S
• Molecular Weight: 3465.0 g/mol
• Solubility: Soluble in water and physiological saline; unstable in alkaline conditions.
• Structure: A single-chain polypeptide containing 31 amino acids, beginning with the Enkephalin sequence (Tyr-Gly-Gly-Phe-Met).

Beta-endorphin Human is a Neuropeptide and Opioid Agonist. Within the EPC system, it is also categorized as an Estrogen, Progesterone, and Cholinergic Nicotinic Agonist. It is closely related to other endogenous peptides like Leu-enkephalin and Dynorphin.